Stock IdeasStrong Buy StocksStrong Buy Stocks from Top Wall Street AnalystsLatest stocks with a Strong Buy rating from the top performing 25% of analysts tracked by WallStreetZen
Stock IdeasStrong Buy Stocks
| Analyst / Firm | Company | Price | Rating | Price Target | Upside/Downside | Date |
|---|---|---|---|---|---|---|
Tg Therapeutics IncTGTX | $32.04 | Strong Buy | $55.00 | +71.66% | 19 hours ago | |
Analyst RankingTop 4% #177 out of 5020 analysts Average Return+32.05% Win Rate42%54 out of 128 Risk vs RewardPoor Good Analyst ColorB. Riley Securities's Mayank Mamtani raised their price target on Tg Therapeutics (NASDAQ: TGTX) by 3.8% from $53 to $55 on 2025/09/17. The analyst maintained their Strong Buy rating on the stock. An expectation that Briumvi is set for multi-year U.S. sales growth accounts for their price target hike, Mamtani said. The drug is tracking to top $1B in sales in the next few years, the analyst detailed. The post-earnings selloff is a buying opportunity, Mamtani told readers. | ||||||
Tesla IncTSLA | $800.00 | Strong Buy | $850.00 | +6.25% | a day ago | |
Upgrade to Premium to View MoreStrong buys: Upgrade to Premium to view the rest of today's Strong Buy stocks from Wall Street's top analysts Already have access to ? Sign In | ||||||
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.